Annual Cash & Cash Equivalents
$5.03 M
-$5.52 M-52.32%
March 31, 2024
Summary
- As of February 20, 2025, PRTG annual cash & cash equivalents is $5.03 million, with the most recent change of -$5.52 million (-52.32%) on March 31, 2024.
- During the last 3 years, PRTG annual cash & cash equivalents has risen by +$2.26 million (+81.52%).
- PRTG annual cash & cash equivalents is now -78.47% below its all-time high of $23.35 million, reached on March 31, 2022.
Performance
PRTG Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$1.76 M
-$1.57 M-47.09%
September 30, 2024
Summary
- As of February 20, 2025, PRTG quarterly cash and cash equivalents is $1.76 million, with the most recent change of -$1.57 million (-47.09%) on September 30, 2024.
- Over the past year, PRTG quarterly cash and cash equivalents has stayed the same.
- PRTG quarterly cash and cash equivalents is now -93.84% below its all-time high of $28.62 million, reached on June 30, 2021.
Performance
PRTG Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PRTG Cash And Cash Equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -52.3% | 0.0% |
3 y3 years | +81.5% | -92.5% |
5 y5 years | -18.5% | -54.1% |
PRTG Cash And Cash Equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -78.5% | +81.5% | -93.1% | at low |
5 y | 5-year | -78.5% | +81.5% | -93.8% | at low |
alltime | all time | -78.5% | >+9999.0% | -93.8% | >+9999.0% |
Portage Biotech Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $1.76 M(-47.1%) |
Jun 2024 | - | $3.33 M(-33.7%) |
Mar 2024 | $5.03 M(-52.3%) | $5.03 M(-5.9%) |
Dec 2023 | - | $5.34 M(+55.0%) |
Sep 2023 | - | $3.44 M(-55.2%) |
Jun 2023 | - | $7.70 M(-27.0%) |
Mar 2023 | $10.54 M(-54.8%) | $10.54 M(-19.5%) |
Dec 2022 | - | $13.10 M(-12.9%) |
Sep 2022 | - | $15.04 M(-29.0%) |
Jun 2022 | - | $21.18 M(-9.3%) |
Mar 2022 | $23.35 M(+743.0%) | $23.35 M(-8.8%) |
Dec 2021 | - | $25.60 M(-6.1%) |
Sep 2021 | - | $27.26 M(-4.7%) |
Jun 2021 | - | $28.62 M(+933.1%) |
Mar 2021 | $2.77 M(-12.1%) | $2.77 M(-23.8%) |
Dec 2020 | - | $3.64 M(-17.9%) |
Sep 2020 | - | $4.43 M(-45.9%) |
Jun 2020 | - | $8.20 M(+160.0%) |
Mar 2020 | $3.15 M(-48.9%) | $3.15 M(+5.3%) |
Dec 2019 | - | $2.99 M(-22.1%) |
Sep 2019 | - | $3.84 M(-25.9%) |
Jun 2019 | - | $5.19 M(-15.9%) |
Mar 2019 | $6.17 M(-18.0%) | $6.17 M(+2.0%) |
Dec 2018 | - | $6.04 M(-14.8%) |
Sep 2018 | - | $7.10 M(-3.2%) |
Jun 2018 | - | $7.33 M(-2.5%) |
Mar 2018 | $7.52 M(+4629.6%) | $7.52 M(+262.8%) |
Dec 2017 | - | $2.07 M(+952.3%) |
Sep 2017 | - | $197.00 K(-56.0%) |
Jun 2017 | - | $448.10 K(+181.8%) |
Mar 2017 | $159.00 K(-96.6%) | $159.00 K(-36.9%) |
Dec 2016 | - | $252.10 K(-46.1%) |
Sep 2016 | - | $467.50 K(-93.7%) |
Jun 2016 | - | $7.47 M(+59.3%) |
Mar 2016 | $4.69 M(+172.9%) | $4.69 M(+59.6%) |
Dec 2015 | - | $2.94 M(-17.6%) |
Sep 2015 | - | $3.57 M(-40.4%) |
Jun 2015 | - | $5.99 M(+248.5%) |
Mar 2015 | $1.72 M(-15.4%) | $1.72 M(-37.0%) |
Dec 2014 | - | $2.73 M(+98.9%) |
Sep 2014 | - | $1.37 M(-16.9%) |
Jun 2014 | - | $1.65 M(-18.8%) |
Mar 2014 | $2.03 M(-38.8%) | $2.03 M(-33.6%) |
Dec 2013 | - | $3.06 M(-6.8%) |
Sep 2013 | - | $3.28 M(-11.2%) |
Jun 2013 | - | $3.70 M(+11.4%) |
Mar 2013 | $3.32 M | $3.32 M(+79.0%) |
Dec 2012 | - | $1.85 M(-17.4%) |
Sep 2012 | - | $2.24 M(+1701.8%) |
Date | Annual | Quarterly |
---|---|---|
Jun 2012 | - | $124.50 K(+112.8%) |
Mar 2012 | $58.50 K(-83.7%) | $58.50 K(-61.4%) |
Dec 2011 | - | $151.50 K(+141.6%) |
Sep 2011 | - | $62.70 K(-39.5%) |
Jun 2011 | - | $103.60 K(-71.1%) |
Mar 2011 | $358.50 K(-84.7%) | $358.50 K(+30.4%) |
Dec 2010 | - | $274.90 K(-19.4%) |
Sep 2010 | - | $340.90 K(-61.9%) |
Jun 2010 | - | $894.80 K(-61.8%) |
Mar 2010 | $2.34 M(+737.6%) | $2.34 M(+484.8%) |
Dec 2009 | - | $400.30 K(+78.5%) |
Sep 2009 | - | $224.30 K(-15.3%) |
Jun 2009 | - | $264.70 K(-5.3%) |
Mar 2009 | $279.50 K(-77.2%) | $279.50 K(-24.5%) |
Dec 2008 | - | $370.10 K(-27.9%) |
Sep 2008 | - | $513.10 K(-34.7%) |
Jun 2008 | - | $786.10 K(-35.7%) |
Mar 2008 | $1.22 M(-53.2%) | $1.22 M(-23.5%) |
Dec 2007 | - | $1.60 M(-28.1%) |
Sep 2007 | - | $2.22 M(-13.8%) |
Jun 2007 | - | $2.58 M(-1.3%) |
Mar 2007 | $2.61 M(-6.6%) | $2.61 M(+41.5%) |
Dec 2006 | - | $1.85 M(-15.5%) |
Sep 2006 | - | $2.19 M(-19.0%) |
Jun 2006 | - | $2.70 M(-3.6%) |
Mar 2006 | $2.80 M(+293.5%) | $2.80 M(+135.1%) |
Dec 2005 | - | $1.19 M(-17.8%) |
Sep 2005 | - | $1.45 M(+210.9%) |
Jun 2005 | - | $465.90 K(-34.5%) |
Mar 2005 | $711.20 K(+86.3%) | $711.20 K(+178.7%) |
Dec 2004 | - | $255.20 K(+1092.5%) |
Sep 2004 | - | $21.40 K(-86.2%) |
Jun 2004 | - | $155.40 K(-59.3%) |
Mar 2004 | $381.70 K(+2727.4%) | $381.70 K(>+9900.0%) |
Dec 2003 | - | $600.00(-98.3%) |
Sep 2003 | - | $35.40 K(-92.0%) |
Jun 2003 | - | $440.60 K(+3163.7%) |
Mar 2003 | $13.50 K(-54.8%) | $13.50 K(>+9900.0%) |
Dec 2002 | - | $100.00(-50.0%) |
Sep 2002 | - | $200.00(-33.3%) |
Jun 2002 | - | $300.00(-99.0%) |
Mar 2002 | $29.90 K(+15.9%) | $29.90 K(+3222.2%) |
Dec 2001 | - | $900.00(-69.0%) |
Sep 2001 | - | $2900.00(-72.1%) |
Jun 2001 | - | $10.40 K(-59.7%) |
Mar 2001 | $25.80 K(-91.2%) | $25.80 K(+62.3%) |
Dec 2000 | - | $15.90 K |
Mar 2000 | $293.30 K(+586.9%) | - |
Mar 1999 | $42.70 K(+967.5%) | - |
Mar 1998 | $4000.00 | - |
FAQ
- What is Portage Biotech annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Portage Biotech?
- What is Portage Biotech annual cash & cash equivalents year-on-year change?
- What is Portage Biotech quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Portage Biotech?
- What is Portage Biotech quarterly cash and cash equivalents year-on-year change?
What is Portage Biotech annual cash & cash equivalents?
The current annual cash & cash equivalents of PRTG is $5.03 M
What is the all time high annual cash & cash equivalents for Portage Biotech?
Portage Biotech all-time high annual cash & cash equivalents is $23.35 M
What is Portage Biotech annual cash & cash equivalents year-on-year change?
Over the past year, PRTG annual cash & cash equivalents has changed by -$5.52 M (-52.32%)
What is Portage Biotech quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PRTG is $1.76 M
What is the all time high quarterly cash and cash equivalents for Portage Biotech?
Portage Biotech all-time high quarterly cash and cash equivalents is $28.62 M
What is Portage Biotech quarterly cash and cash equivalents year-on-year change?
Over the past year, PRTG quarterly cash and cash equivalents has changed by $0.00 (0.00%)